dc.contributor.author | Haynes, BP | |
dc.contributor.author | Schuster, G | |
dc.contributor.author | Buus, R | |
dc.contributor.author | Alataki, A | |
dc.contributor.author | Ginsburg, O | |
dc.contributor.author | Quang, LH | |
dc.contributor.author | Han, PT | |
dc.contributor.author | Khoa, PH | |
dc.contributor.author | Van Dinh, N | |
dc.contributor.author | Van To, T | |
dc.contributor.author | Clemons, M | |
dc.contributor.author | Holcombe, C | |
dc.contributor.author | Osborne, C | |
dc.contributor.author | Evans, A | |
dc.contributor.author | Skene, A | |
dc.contributor.author | Sibbering, M | |
dc.contributor.author | Rogers, C | |
dc.contributor.author | Laws, S | |
dc.contributor.author | Noor, L | |
dc.contributor.author | Cheang, MCU | |
dc.contributor.author | Cleator, SJ | |
dc.contributor.author | Smith, IE | |
dc.contributor.author | Dowsett, M | |
dc.date.accessioned | 2021-12-07T15:03:40Z | |
dc.date.available | 2021-12-07T15:03:40Z | |
dc.date.issued | 2021-11-01 | |
dc.identifier.citation | Breast cancer research and treatment, 2021, 190 (2), pp. 295 - 305 | |
dc.identifier.issn | 0167-6806 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4918 | |
dc.identifier.eissn | 1573-7217 | |
dc.identifier.doi | 10.1007/s10549-021-06377-3 | |
dc.description.abstract | PURPOSE: Changes occur in the expression of oestrogen-regulated and proliferation-associated genes in oestrogen receptor (ER)-positive breast tumours during the menstrual cycle. We investigated if Oncotype® DX recurrence score (RS), Prosigna® (ROR) and EndoPredict® (EP/EPclin) prognostic tests, which include some of these genes, vary according to the time in the menstrual cycle when they are measured. METHODS: Pairs of test scores were derived from 30 ER-positive/human epidermal growth factor receptor-2-negative tumours sampled at two different points of the menstrual cycle. Menstrual cycle windows were prospectively defined as either W1 (days 1-6 and 27-35; low oestrogen and low progesterone) or W2 (days 7-26; high oestrogen and high or low progesterone). RESULTS: The invasion module score of RS was lower (- 10.9%; p = 0.098), whereas the ER (+ 16.6%; p = 0.046) and proliferation (+ 7.3%; p = 0.13) module scores were higher in W2. PGR expression was significantly increased in W2 (+ 81.4%; p = 0.0029). Despite this, mean scores were not significantly different between W1 and W2 for any of the tests and the two measurements showed high correlation (r = 0.72-0.93). However, variability between the two measurements led to tumours being assigned to different risk categories in the following proportion of cases: RS 22.7%, ROR 27.3%, EP 13.6% and EPclin 13.6%. CONCLUSION: There are significant changes during the menstrual cycle in the expression of some of the genes and gene module scores comprising the RS, ROR and EP/EPclin scores. These did not affect any of the prognostic scores in a systematic fashion, but there was substantial variability in paired measurements. | |
dc.format | Print-Electronic | |
dc.format.extent | 295 - 305 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | SPRINGER | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Humans | |
dc.subject | Breast Neoplasms | |
dc.subject | Neoplasm Recurrence, Local | |
dc.subject | Receptors, Estrogen | |
dc.subject | Prognosis | |
dc.subject | Menstrual Cycle | |
dc.subject | Female | |
dc.title | Impact of the menstrual cycle on commercial prognostic gene signatures in oestrogen receptor-positive primary breast cancer. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2021-08-26 | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1007/s10549-021-06377-3 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Breast cancer research and treatment | |
pubs.issue | 2 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrinology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology/Endocrinology (hon.) | |
pubs.publication-status | Published | |
pubs.volume | 190 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Clinical Trials & Statistics Unit | |
icr.researchteam | Endocrinology | |
dc.contributor.icrauthor | Schuster, Eugene | |
dc.contributor.icrauthor | Alataki, Anastasia | |
dc.contributor.icrauthor | Cheang, Chon | |